| 14.94 -0.44 (-2.86%) | 03-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 18.29 |
1-year : | 19.62 |
| Resists | First : | 15.66 |
Second : | 16.79 |
| Pivot price | 15.65 |
|||
| Supports | First : | 13.82 |
Second : | 11.5 |
| MAs | MA(5) : | 15.64 |
MA(20) : | 15.45  |
| MA(100) : | 17.44 |
MA(250) : | 20.79 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 44.1 |
| RSI | RSI(14): 42.6 |
|||
| 52-week | High : | 36.9 | Low : | 13.82 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SMMT ] has closed above bottom band by 16.0%. Bollinger Bands are 36.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 15.16 - 15.24 | 15.24 - 15.31 |
| Low: | 14.45 - 14.55 | 14.55 - 14.64 |
| Close: | 14.77 - 14.92 | 14.92 - 15.06 |
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Wed, 04 Mar 2026
Why Summit Therapeutics (SMMT) Is Down 6.3% After Wider 2025 Loss and ESOP Shelf Filing - simplywall.st
Tue, 03 Mar 2026
Is Summit Therapeutics (SMMT) Now Pricing In Too Much Hope After Strong Multi Year Gains - simplywall.st
Tue, 03 Mar 2026
Rafferty Asset Management LLC Purchases 140,323 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Tue, 03 Mar 2026
Is Summit Therapeutics (SMMT) Pricing Reflect Long Term Value After Recent Share Price Swings - Yahoo Finance
Tue, 03 Mar 2026
Summit Therapeutics (SMMT) Ends 2025 With Strong Cash Reserves and Increased Clinical Investment - Finviz
Mon, 02 Mar 2026
Summit Therapeutics Inc. (SMMT) Stock Analysis: Biotech Innovator with an 89.92% Potential Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 744 (M) |
| Shares Float | 125 (M) |
| Held by Insiders | 86 (%) |
| Held by Institutions | 16.1 (%) |
| Shares Short | 36,960 (K) |
| Shares Short P.Month | 37,010 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.25 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -152.9 % |
| Return on Equity (ttm) | -292.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -270 (M) |
| Levered Free Cash Flow | 74 (M) |
| PE Ratio | -11.96 |
| PEG Ratio | 0 |
| Price to Book value | 57.46 |
| Price to Sales | 0 |
| Price to Cash Flow | -41.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|